One in five UK doctors use AI chatbots
A survey led by researchers at Uppsala University in Sweden reveals that a significant proportion of UK general practitioners (GPs) are integrating generative AI tools, such as ChatGPT,… read more.
A survey led by researchers at Uppsala University in Sweden reveals that a significant proportion of UK general practitioners (GPs) are integrating generative AI tools, such as ChatGPT,… read more.
Up to 74% of adults with treatment-resistant high blood pressure were able to get their blood pressure below 140/90 mm HG within one year through a program combining… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.
Nearly three-quarters of Dutch elite athletes and forty percent of their coaches report sport-related distress. This is one of the findings from a study conducted by Amsterdam UMC… read more.
One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, allowing it to evade the antibody response… read more.
Genentech, a member of the Roche Group , announced t positive topline results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral, showing a reduction in… read more.
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer. Two studies focus on breastfeeding after breast cancer diagnosis and treatment. The studies found… read more.
Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is… read more.
NICE:(UK): Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti?CD20-based treatment. It is… read more.
Norway introduced its Regular GP Scheme was introduced in 2001. This gave all citizens the right to choose a GP in their home municipality and facilitates personal continuity… read more.
Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for… read more.
The findings of the study are of particular interest to employers, who sometimes invest a lot of money to improve the work satisfaction and motivation of their employees…. read more.